Akari Therapeutics, Plc (AKTX) Trading at $3.85 after Decrease on Mar, 15

Akari Therapeutics, Plc (NASDAQ:AKTX) Corporate Logo

Akari Therapeutics, Plc (NASDAQ:AKTX) declined considerably to $3.85. Barchart.com posted the move on Mar, 15. It has $60.82M MC. $4.26 million less could be NASDAQ:AKTX valuation at $3.58 share price.

For more Akari Therapeutics, Plc (NASDAQ:AKTX) news released recently go to: Globenewswire.com, Nasdaq.com, Globenewswire.com, Globenewswire.com or Benzinga.com. The titles are as follows: “Akari Therapeutics Announces Appointment of David Horn Solomon as CEO – GlobeNewswire” released on August 21, 2017, “European ADRs Move Higher in Wednesday Trading – Nasdaq” on March 13, 2019, “Akari Therapeutics Receives Notice Related to Delay in 20-F Filing – GlobeNewswire” with a publish date: May 21, 2018, “Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC – GlobeNewswire” and the last “Why Thinly Traded Biotech Akari Therapeutics (NASDAQ:AKTX) Is Jumping More Than 150% – Benzinga” with publication date: March 13, 2019.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases.The firm is worth $60.82 million. The Company’s lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.Last it reported negative earnings. The firm is based in New York, New York.

Akari Therapeutics, Plc (NASDAQ:AKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.